cas 403-43-0|| where to buy 4-Fluorobenzoyl chloride

Produktname:4-Fluorobenzoyl chloride

IUPAC Name:4-fluorobenzoyl chloride

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM343690-100g	1-2 Weeks	Ǖǧ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 403-43-0 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:403-43-0; Molekulare Formel:C7H4ClFO; Schmelzpunkt:-; SMILES-Code:O=C(Cl)C1=CC=C(F)C=C1; Dichte:

: Katalognummer:CM343690; Molekulargewicht:158.56; Siedepunkt:; Mdl-Nr.:MFCD00000684; Lagerung:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Fezolinetant; Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.